Anti-inflammatory and hypolipidemic effects of the modified fatty acid tetradecylthioacetic acid in psoriasis - A pilot study

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 71, Issue 4, 2011, Pages 269-273

  Morken, Tore ^a   Bohov, Pavol ^a   Skorve, Jon ^a   Ulvik, Rune ^a,b   Aukrust, Pål ^c,d   Berge, Rolf K ^a   Livden, John K ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

anti inflammatory agents; anticholesteremic agents; cardiovascular diseases; lipids; peroxisome proliferator activated receptors; Psoriasis

Indexed keywords

CHOLESTEROL; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOUNSATURATED FATTY ACID; OMEGA 3 FATTY ACID; PLACEBO; TETRADECYLTHIOACETIC ACID; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; HYPOLIPIDEMIC ACTIVITY; MALE; PILOT STUDY; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; INTERLEUKIN-8; LIPIDS; MALE; MIDDLE AGED; PILOT PROJECTS; PSORIASIS; SULFIDES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1; YOUNG ADULT;

THIA;

EID: 79958798362     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2011.559552     Document Type: Article

References (27)

1. Berge RK, Skorve J, Tronstad KJ, Berge K, Gudbrandsen OA, Grav H. Metabolic effects of thia fatty acids. Curr Opin Lipidol 2002;13:295-304. (Pubitemid 34592287)
2. Raspé E, Madsen L, Lefebvre AM, Leitersdorf I, Gelman L, Peinado-Onsurbe J, Dallongeville J, Fruchart JC, Berge R, Staels B. Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPARalpha activation. J Lipid Res 1999;40:2099-110. (Pubitemid 29523436)
3. Dyroy E, Yndestad A, Ueland T, Halvorsen B, Damas JK, Aukrust P, Berge RK. Antiinflammatory effects of tetrade-cylthioacetic acid involve both peroxisome proliferator-activated receptor alpha-dependent and -independent pathways. Arterioscler Thromb Vasc Biol 2005;25:1364-9. (Pubitemid 40923353)
4. Muna ZA, Doudin K, Songstad J, Ulvik RJ, Berge RK. Tetradecylthioacetic acid inhibits the oxidative modification of low density lipoprotein and 8-hydroxydeoxyguanosine formation in vitro. Arterioscler Thromb Vasc Biol 1997;17:3255-62. (Pubitemid 28016086)
5. Aukrust P, Wergedahl H, Mü ller F, Ueland T, Dyrøy E, Damås JK, Frøland SS, Berge RK. Immunomodulating effects of 3-thia fatty acids in activated peripheral blood mononuclear cells. Eur J Clin Invest 2003;33:426-33. (Pubitemid 36583712)
6. Fredriksen J, Ueland T, Dyrøy E, Halvorsen B, Melby K, Melbye L, Skalhegg BS, Bohov P, Skorve J, Berge RK, Aukrust P, Frøland SS. Lipid-lowering and anti-inflammatory effects of tetradecylthioacetic acid in HIV-infected patients on highly active antiretroviral therapy. Eur J Clin Invest 2004;34:709-15. (Pubitemid 39423029)
7. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001;303:33-9. (Pubitemid 32121803)
8. Ikai K. Psoriasis and the arachidonic acid cascade. J Dermatol Sci 1999;21:135-46. (Pubitemid 29430219)
9. Vanizor KB, Orem A, Cimsit G, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003;328:71-82. (Pubitemid 36135781)
10. Piskin S, Gurkok F, Ekuklu G, Senol M. Serum lipid levels in psoriasis. Yonsei Med J 2003;44:24-6. (Pubitemid 36322510)
11. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figneiredo A, Quintanilha A, Teixeira F. Erythrocyte damage in mild and severe psoriasis. Br J Dermatol 2004;150:232-44. (Pubitemid 38352460)
12. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, Ståhle-Bäckdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-30. (Pubitemid 38461682)
13. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35. (Pubitemid 44556851)
14. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41. (Pubitemid 44547793)
15. Cohen AD, Gilutz H, Henkin Y, Zahger D, Shapiro J, Bonneh DY, Vardy DA. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007;87:506-9. (Pubitemid 351373394)
16. Proksch E. [Antilipemic drug-induced skin manifestations]. Hautarzt 1995;46:76-80.
17. Jacobi TC, Highet A. A clinical dilemma while treating hypercholesterolaemia in psoriasis. Br J Dermatol 2003;149:1305-6. (Pubitemid 38058120)
18. Gottlied AB, Chaudhari U, Baker DG, Perate M, Dooley LT. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol 2003;2:260-6.
19. Berge K, Tronstad KJ, Bohov P, Madsen L, Berge RK. Impact of mitochondrial beta-oxidation in fatty acid-mediated inhibition of glioma cell proliferation. J Lipid Res 2003;44:118-27. (Pubitemid 36114777)
20. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, Kaufmann R, Vogl TJ, Boehncke WH Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007;156:271-6. (Pubitemid 46095954)
21. Lee ML, To T, Nicholson E, Schrieber L. Endothelial cell adhesion molecules in psoriasis. Australas J Dermatol 1994;35:65-70.
22. Watabe D, Kanno H, Yoshida A, Kurose A, Akasaka T, Sawai T. Adhesion of peripheral blood mononuclear cells and CD4 + T cells from patients with psoriasis to cultured endothelial cells via the interaction between lymphocyte function-associated antigen type 1 and intercellular adhesion molecule 1. Br J Dermatol 2007Aug;157:259-65.
23. Ogilvie AL, Luftl M, Antoni C, Schuler G, Kalden JR, Lorenz HM. Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-alpha. Int J Immunopathol Pharmacol 2006;19:271-8. (Pubitemid 44181950)
24. Zalewska A, Glowacka E, Wyczolkowska J, Tchorzewski H, Narbutt J, Sysa-Jedrzejowska A. Interleukin 6 and 8 levels in plasma and fibroblast cultures in psoriasis. Mediators Inflamm 2006;2006:81767.
25. Schleyer V, Landthaler M, Szeimies RM. Novel pharmacological approaches in the treatment of psoriasis. J Eur Acad Dermatol Venereol 2005;19:1-20. (Pubitemid 40276783)
26. Wiedmann MW, Mössner J, Baerwald C, Pierer M. TNF alpha inhibition as treatment modality for certain rheumatologic and gastrointestinal diseases. Endocr Metab Immune Disord Drug Targets 2009;9:295-314.
27. Parthasarathy S, Khoo JC, Miller E, Barnett J, Witztum JL, Steinberg D. Low density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis. Proc Natl Acad Sci USA 1990;87:3894-8.